จำหน่ายเกจวัดแรงดัน Pressure Gauge ทุกยี่ห้อ

ศูนย์รวมเครื่องมือวัดความดัน

Acquisition will add to Dover’s single-use element offering

Dover has entered right into a definitive agreement to amass Malema Engineering Corp, a US designer and producer of high-precision, mission-critical flow-measurement and management devices for the biopharmaceutical, semiconductor and industrial sectors.
Image: dizain/Adobe Stock.
Malema’s merchandise will expand Dover’s biopharma single-use production offering, which already consists of Quattroflow pumps, CPC connectors, and em-tec flowmeters.
Based in Boca Raton, Florida, and with facilities in San Jose, California, Singapore, South Korea and India, Malema expects to generate approximately US$40 million–45 million in revenue in the course of the full yr 2022.
When เกจวัดแรงดันไฟฟ้า closes, Malema will become part of the PSG business unit inside Dover’s Pumps & Process Solutions section.
“We see an incredible long-term progress alternative in the bioprocessing trade pushed by a powerful and growing pipeline of effective novel biologic drugs, biosimilars, protein therapies, non-COVID mRNA vaccines, as well as budding cell & gene therapies,” says PSG’s president Karl Buscher. “Additionally, the growing adoption of extra efficient single-use production processes helps a sturdy outlook for our offerings of single-use components to end-customers. We believe that pairing Malema’s technology with our current portfolio of single-use pumps for biopharma processing will greatly enhance the accuracy and worth proposition of our solutions to our prospects.”
“We are methodically building out our biopharma platform via proactive capacity additions, new product development, and opportunistic acquisitions of highly-attractive area of interest part applied sciences,” said Richard Tobin, president and CEO of Dover. “Malema represents a strategic and highly-complementary flow-control and sensing know-how and further strengthens our sensor portfolio with new proprietary know-how. In addition to attractive biopharma functions, we expect sturdy growth within the semiconductor space on the capacity enlargement and re-shoring tailwinds.”
Share